Support for your adolescent and adult patients
Providing you with practical tips and advice for your adult patients receiving Nucala.
Nucala is available for at home or in office use
Nucala is available in 3 administration options for adolescents and adults:1
- Pre-filled Pen for patients to use at home
- Pre-filled Syringe for HCPs or caregivers to use in office
- Lyophilised powder for reconstitution by an HCP in office
The licensed dose of Nucala in children aged 6-11 years is 40mg SC regardless of weight and available in lyophilised powder.1
Nucala is administered as a single injection, once every 4 weeks. Patients may need to plan for about 13 injections every year.1
Around one-fifth of patients have a fear of needles which could lead to avoidance of medical care. It is important to understand this in determining the best treatment option.2
It may be useful to spend some time with your patient to help plan how they will fit their injections into their schedule and whether at home or in office administration makes the most sense. If they need to travel for their injections, it is worth identifying possible problems that they may need to overcome, such as arranging:
- Time off work, and how to talk to their employer
- Child care if they have young children
- Transport to the clinic or researching local public transport links
Nucala may be self-administered by the patient or administered by a caregiver if their healthcare professional determines that it is appropriate, and the patient or caregiver are trained in injection techniques.1
Nucala is a long-term treatment that requires planning
It is important to remind your patients that Nucala is intended for long-term treatment. The need for continued therapy should be considered at least on an annual basis as determined by assessment of the patient’s disease severity and level of control of exacerbations.1
At home administration - Using the Pre-filled pen
Some patients may benefit from taking Nucala at home because of the additional convenience. By training them in your office, they should be able to administer their dose of Nucala.
In a clinical trial 98-99% of patients were able to successfully self administer using the Nucala pre-filled pen after training and 92% and 86% reported finding it easy to use.*3
If your patients are using the Pre-filled Pen, a step by step guide is available to help them with administration.
This technical step by step guide is intended for patients who have been prescribed Nucala for injection at home and it can also be found together with the package leaflet at Felleskatalogen.
In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections.1
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, pre-filled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC regardless of weight and available in lyophilised powder.
Pre-filled pen and syringe can be administered by the patient himself or by the caregiver if the health care professional has deemed it appropriate and training in injection technique is provided. Inform the patient to seek medical attention immediately if allergic reactions occur during / after injection.
Read the PI text before prescribing Nucala. In case of adverse medical events, contact GSK on telephone: 22 70 20 00
* A 12-week open-label, single-arm study assessing correct use of the Nucala pre-filled pen in 159 patients with SEA following training on proper pen technique at baseline. One group used a pen with pictogram (n=104) and one without pictogram label (n=55). Successful use was determined using a checklist of steps based on instructions for use and visual inspection of the pen (155 of 157 attempted injections). Ease of use was measured through a patient questionnaire at the end of the study using a 5-point scale (not at all, a little, moderately, very and extremely). Of the patients who successfully self-administered at primary endpoint week 8 (n=155), 151 patients completed the questionnaire. Two patients were withdrawn from the study (1 physician decision and 1 adverse event). Primary endpoint (successful injection week 8, third dose of Nucala) was achieved by 99% (102/103, 95% CI 95-100%) using pen with pictogram label and 98% (53/54, 95% CI 90-100%) using pen with standard label. 92% (94/102) of patients using the pen with pictogram and 86% (44/51) of patients using the pen without pictogram found Nucala pen "very" or "extremely" easy to self-administer at home.1